Caladrius Biosciences

Basic Information

106 Allen Road, 4th Floor
Basking Ridge, NJ, 07920

http://www.caladrius.com

Company Profile

Caladrius Biosciences, Inc., through its subsidiary, PCT, is a leading development and manufacturing partner to the cell therapy industry. PCT works with its clients to overcome the fundamental challenges of cell therapy manufacturing by providing a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support. PCT and Hitachi Chemical Co., Ltd. have entered into a strategic global collaboration to accelerate the creation of a global commercial cell therapy development and manufacturing enterprise with deep engineering expertise. Around the core expertise of PCT, Caladrius strategically develops select product candidates, which currently includes an innovative therapy for type 1 diabetes based on a proprietary platform technology for immunomodulation. For more information, visit www.caladrius.com.

Additional Details

Field Value
DUNS: 424034510
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 200


  1. Development of Adult Pluripotent Very Small Embryonic Like (VSEL) Stem Cells to T

    Amount: $147,765.00

    DESCRIPTION (provided by applicant): Scleroderma is an autoimmune, connective tissue disorder which causes fibrosis of the skin and internal organs. In the skin, there is overproduction of extracellul ...

    SBIR Phase I 2013 Department of Health and Human Services
  2. Repair of Bone Defects with Human Autologous Pluripotent Very Small Embryonic lik

    Amount: $1,221,854.00

    DESCRIPTION (provided by applicant): Bone loss due to fractures and disease is a serious medical condition in the US affecting millions of Americans. It is particularly a problem with oral craniofaci ...

    SBIR Phase II 2012 Department of Health and Human Services
  3. Development of Human, Autologous, Pluripotent Very Small Embryonic Like (VSELs) s

    Amount: $595,252.00

    DESCRIPTION (provided by applicant): In the event of a nuclear accident or terrorist bomb, large numbers of casualties will have been exposed to acute high-dose radiation. Those exposed will have co ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. Repair of boney defects by human stem cells

    Amount: $108,746.00

    DESCRIPTION (provided by applicant): In alignment with Healthy People 2010 (Arthritis/Osteoporosis) and research objectives established by the NIAMS, the overall goal of this study is to prevent illne ...

    SBIR Phase I 2009 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government